Clinical Trial Update: Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination Tablet With Ribavirin for 12 Weeks in Treatment-naive Adults With Chronic HCV Genotype 3 Infection [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety and efficacy of a ledipasvir/sofosbuvir fixed-dose combination tablet with ribavirin for 12 weeks in treatment-naive adults with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Ledipasvir/sofosbuvir (Ledipasvir and sofosbuvir)
• Ribavirin (ribavirin)

Snippet

Sponsor: Gilead Sciences | Conditions: Hepatitis C Virus Infection | Phase 2 | Status: COMPLETED | Results posted: 2017-02-14